Cargando…

Validation of LDLr Activity as a Tool to Improve Genetic Diagnosis of Familial Hypercholesterolemia: A Retrospective on Functional Characterization of LDLr Variants

Familial hypercholesterolemia (FH) is an autosomal dominant disorder characterized by high blood-cholesterol levels mostly caused by mutations in the low-density lipoprotein receptor (LDLr). With a prevalence as high as 1/200 in some populations, genetic screening for pathogenic LDLr mutations is a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benito-Vicente, Asier, Uribe, Kepa B., Jebari, Shifa, Galicia-Garcia, Unai, Ostolaza, Helena, Martin, Cesar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032215/ https://www.ncbi.nlm.nih.gov/pubmed/29874871 http://dx.doi.org/10.3390/ijms19061676

Ejemplares similares

MLb-LDLr: A Machine Learning Model for Predicting the Pathogenicity of LDLr Missense Variants
por: Larrea-Sebal, Asier, et al.
Publicado: (2021)

Mutation type classification and pathogenicity assignment of sixteen missense variants located in the EGF-precursor homology domain of the LDLR
por: Galicia-Garcia, Unai, et al.
Publicado: (2020)

Familial Hypercholesterolemia: The Most Frequent Cholesterol Metabolism Disorder Caused Disease
por: Benito-Vicente, Asier, et al.
Publicado: (2018)

Predictive Modeling and Structure Analysis of Genetic Variants in Familial Hypercholesterolemia: Implications for Diagnosis and Protein Interaction Studies
por: Larrea-Sebal, Asier, et al.
Publicado: (2023)

Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity
por: Banerjee, Poulabi, et al.
Publicado: (2019)

Statin Treatment-Induced Development of Type 2 Diabetes: From Clinical Evidence to Mechanistic Insights
por: Galicia-Garcia, Unai, et al.
Publicado: (2020)

Pathophysiology of Type 2 Diabetes Mellitus
por: Galicia-Garcia, Unai, et al.
Publicado: (2020)

Cholesterol Efflux Efficiency of Reconstituted HDL Is Affected by Nanoparticle Lipid Composition
por: Jebari-Benslaiman, Shifa, et al.
Publicado: (2020)

Advantages and Versatility of Fluorescence-Based Methodology to Characterize the Functionality of LDLR and Class Mutation Assignment
por: Etxebarria, Aitor, et al.
Publicado: (2014)

Age, Origin and Functional Study of the Prevalent LDLR Mutation Causing Familial Hypercholesterolaemia in Gran Canaria
por: Suárez, Nicolás M., et al.
Publicado: (2023)

Endoplasmic reticulum quality control of LDLR variants associated with familial hypercholesterolemia
por: Kizhakkedath, Praseetha, et al.
Publicado: (2019)

Therapeutic targets of hypercholesterolemia: HMGCR and LDLR
por: Ma, Shizhan, et al.
Publicado: (2019)

Cardiovascular Disease, Atherosclerosis and Familial Hypercholesterolemia: From Molecular Mechanisms Causing Pathogenicity to New Therapeutic Approaches
por: Jebari-Benslaiman, Shifa, et al.
Publicado: (2023)

The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia
por: Meshkov, Alexey, et al.
Publicado: (2021)

A novel indel variant in LDLR responsible for familial hypercholesterolemia in a Chinese family
por: Shu, Hongyan, et al.
Publicado: (2017)

Two Novel Disease-Causing Mutations in the LDLR of Familial Hypercholesterolemia
por: Hu, Haochang, et al.
Publicado: (2021)

LDLR gene’s promoter region hypermethylation in patients with familial hypercholesterolemia
por: Zorzo, R. A., et al.
Publicado: (2023)

The LDLR c.501C>A is a disease-causing variant in familial hypercholesterolemia
por: Hu, Haochang, et al.
Publicado: (2021)

Novel Presentation of Homozygous Familial Hypercholesterolemia With Homozygous Variants in Both LDLR and APOB Genes
por: Derenbecker, Robert, et al.
Publicado: (2019)

In vitro assessment of the pathogenicity of the LDLR c.2160delC variant in familial hypercholesterolemia
por: Lin, Shaoyi, et al.
Publicado: (2023)

Identification of novel variants in the LDLR gene in Russian patients with familial hypercholesterolemia using targeted sequencing
por: Miroshnikova, Valentina V., et al.
Publicado: (2021)

Novel LDLR Variant in Familial Hypercholesterolemia: NGS-Based Identification, In Silico Characterization, and Pharmacogenetic Insights
por: Athar, Mohammad, et al.
Publicado: (2023)

Genomic characterization of large rearrangements of the LDLR gene in Czech patients with familial hypercholesterolemia
por: Goldmann, Radan, et al.
Publicado: (2010)

A Japanese case of familial hypercholesterolemia with a novel mutation in the LDLR gene
por: Nagahara, Keiko, et al.
Publicado: (2019)

Exosome-based Ldlr gene therapy for familial hypercholesterolemia in a mouse model
por: Li, Zhelong, et al.
Publicado: (2021)

Screening and verifying the mutations in the LDLR and APOB genes in a Chinese family with familial hypercholesterolemia
por: Lv, Xian, et al.
Publicado: (2023)

Patients With LDLR and PCSK9 Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia
por: Doi, Takahito, et al.
Publicado: (2021)

Targeted Disruption of LDLR Causes Hypercholesterolemia and Atherosclerosis in Yucatan Miniature Pigs
por: Davis, Bryan T., et al.
Publicado: (2014)

A genetic variant in the LDLR promoter is responsible for part of the LDL-cholesterol variability in primary hypercholesterolemia
por: De Castro-Orós, Isabel, et al.
Publicado: (2014)

Use of next-generation sequencing to detect LDLR gene copy number variation in familial hypercholesterolemia
por: Iacocca, Michael A., et al.
Publicado: (2017)

Analysis of the low density lipoprotein receptor gene (LDLR) mutation spectrum in Russian familial hypercholesterolemia
por: Vasilyev, V.B., et al.
Publicado: (2022)

Decreased serum PON1 arylesterase activity in familial hypercholesterolemia patients with a mutated LDLR gene
por: Idrees, Muhammad, et al.
Publicado: (2018)

Identification of a novel nonsense variant c.1332dup, p.(D445*) in the LDLR gene that causes familial hypercholesterolemia
por: Al-Allaf, Faisal A, et al.
Publicado: (2014)

An LDLR missense variant poses high risk of familial hypercholesterolemia in 30% of Greenlanders and offers potential of early cardiovascular disease intervention
por: Jørsboe, Emil, et al.
Publicado: (2022)

Pathophysiology of Atherosclerosis
por: Jebari-Benslaiman, Shifa, et al.
Publicado: (2022)

A Systematic Approach to Assess the Activity and Classification of PCSK9 Variants
por: Uribe, Kepa B., et al.
Publicado: (2021)

Triciribine increases LDLR expression and LDL uptake through stabilization of LDLR mRNA
por: Bjune, Katrine, et al.
Publicado: (2018)

Saudi Familial Hypercholesterolemia Patients With Rare LDLR Stop Gain Variant Showed Variable Clinical Phenotype and Resistance to Multiple Drug Regimen
por: Awan, Zuhier Ahmed, et al.
Publicado: (2021)

Genetic Polymorphisms in LDLR, APOB, PCSK9 and Other Lipid Related Genes Associated with Familial Hypercholesterolemia in Malaysia
por: Lye, Say-Hean, et al.
Publicado: (2013)

Variable expressivity and co‐occurrence of LDLR and LDLRAP1 mutations in familial hypercholesterolemia: failure of the dominant and recessive dichotomy
por: Fahed, Akl C., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_kfrbialg8qmv07oginb6tq3bnc